For research use only. Not for therapeutic Use.
BAY 41-2272（Cat No.:I002874） is a pharmacological compound known as a soluble guanylate cyclase (sGC) activator. It acts by binding to the heme moiety of sGC and enhances the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). By activating sGC, BAY 41-2272 increases intracellular levels of cGMP, which in turn leads to various physiological effects such as vasodilation, smooth muscle relaxation, and inhibition of platelet aggregation. It is utilized in research and pharmaceutical development for investigating the role of the nitric oxide-cGMP pathway and potential therapeutic applications.
| Catalog Number | I002874 |
| CAS Number | 256376-24-6 |
| Synonyms | 5-cyclopropyl-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-amine |
| Molecular Formula | C20H17FN6 |
| Purity | ≥95% |
| Target | Guanylate Cyclase |
| Solubility | DMSO: ≤ 17.5 mg/mL |
| Storage | 2-8°C |
| IUPAC Name | 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine |
| InChI | InChI=1S/C20H17FN6/c21-16-6-2-1-4-13(16)11-27-20-14(5-3-9-23-20)17(26-27)19-24-10-15(12-7-8-12)18(22)25-19/h1-6,9-10,12H,7-8,11H2,(H2,22,24,25) |
| InChIKey | ATOAHNRJAXSBOR-UHFFFAOYSA-N |
| SMILES | C1CC1C2=CN=C(N=C2N)C3=NN(C4=C3C=CC=N4)CC5=CC=CC=C5F |
| Reference | </br>1:BAY 41-2272 Treatment Improves Acetylcholine-Induced Aortic Relaxation in L-NAME Hypertensive Rats. Prawez S, Ahanger AA, Singh TU, Mishra SK, Sarkar SN, Kumar D.Int J Angiol. 2016 Dec;25(4):235-240. Epub 2016 Apr 4. PMID: 27895434 </br>2:Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility. Calmasini FB, Alexandre EC, Silva FH, De Nucci G, Antunes E, D/’Ancona CA, Mónica FZ.Urology. 2016 Aug;94:312.e9-312.e15. doi: 10.1016/j.urology.2016.04.023. Epub 2016 Apr 27. PMID: 27131967 </br>3:Antenatal BAY 41-2272 reduces pulmonary hypertension in the rabbit model of congenital diaphragmatic hernia. Vuckovic A, Herber-Jonat S, Flemmer AW, Strizek B, Engels AC, Jani JC.Am J Physiol Lung Cell Mol Physiol. 2016 Apr 1;310(7):L658-69. doi: 10.1152/ajplung.00178.2015. Epub 2016 Feb 12. PMID: 26873974 Free PMC Article</br>4:BAY 41-2272 activates host defence against local and disseminated Candida albicans infections. Soeiro-Pereira PV, Falcai A, Kubo CA, Antunes E, Condino-Neto A.Mem Inst Oswaldo Cruz. 2015 Feb;110(1):75-85. doi: 10.1590/0074-02760140255. Epub 2015 Jan 23. PMID: 25742266 Free PMC Article</br>5:Beneficial effect of the soluble guanylyl cyclase stimulator BAY 41-2272 on impaired penile erection in db/db-/- type II diabetic and obese mice. Nunes KP, Teixeira CE, Priviero FB, Toque HA, Webb RC.J Pharmacol Exp Ther. 2015 May;353(2):330-9. doi: 10.1124/jpet.114.220970. Epub 2015 Mar 4. PMID: 25740897 Free Article</br>6:BAY 41-2272 activates host defence against local and disseminated Candida albicans infections. Soeiro-Pereira PV, Falcai A, Kubo CA, Antunes E, Condino-Neto A.Mem Inst Oswaldo Cruz. 2015 Jan 23:0. [Epub ahead of print] PMID: 25626456 </br>7:Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor. Füllhase C, Hennenberg M, Sandner P, Strittmatter F, Niedworok C, Bauer RM, Gratzke C, Soler R, Stief C, Andersson KE.Neurourol Urodyn. 2015 Nov;34(8):787-93. doi: 10.1002/nau.22665. Epub 2014 Sep 17. PMID: 25230878 </br>8:BAY 41-2272, a soluble guanylate cyclase stimulator, relaxes isolated human ureter in a standardized in vitro model. Miyaoka R, Mendes C, Schenka A, Gonzalez PG, de Nucci G, Antunes E, Monga M, Levi D/’Ancona CA, Mónica FZ.Urology. 2014 Jan;83(1):256.e1-7. doi: 10.1016/j.urology.2013.09.005. Epub 2013 Nov 11. PMID: 24231204 </br>9:Picosecond to second dynamics reveals a structural transition in Clostridium botulinum NO-sensor triggered by the activator BAY-41-2272. Yoo BK, Lamarre I, Rappaport F, Nioche P, Raman CS, Martin JL, Negrerie M.ACS Chem Biol. 2012 Dec 21;7(12):2046-54. doi: 10.1021/cb3003539. Epub 2012 Oct 2. PMID: 23009307 </br>10:Vas deferens smooth muscle responses to the nitric oxide-independent soluble guanylate cyclase stimulator BAY 41-2272. da Silva FH, Claudino MA, Báu FR, Rojas-Moscoso JA, Mónica FZ, De Nucci G, Antunes E.Eur J Pharmacol. 2012 Aug 5;688(1-3):49-55. doi: 10.1016/j.ejphar.2012.05.009. Epub 2012 May 22. PMID: 22634166 |
